US FDA places clinical hold on Rocket Pharma's gene therapy trial
27/05/2025 12:23
May 27 (Reuters) - The U.S. Food and Drug Administration placed a clinical hold on Rocket Pharmaceuticals' RCKT.O gene therapy trial due to a serious event in one patient, the company said on Tuesday. (Reporting by Christy Santhosh in Bengaluru; Editing by Savio D'Souza) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08